Closing Cancer Cases Not Under Active Care

Slides:



Advertisements
Similar presentations
EUROCHIP PILOT STUDIES. Collection of detailed clinical information for specific tumours Describing and comparing care in representative samples of cancer.
Advertisements

Children and Young People Improving Outcomes Guidance  Key aims of guidance and age specific requirements  Designation of Principal Treatment Centres.
Cancer Clinical Trials: The Way We Make Progress Against Cancer.
Improving the quality of medical and surgical care NCEPOD SEPSIS STUDY.
100k Genomes Project In December 2012 the Prime Minister announced a programme of Whole Genome Sequencing as part of the UK Government’s Life Sciences.
Instrumenting the Healthcare Enterprise for Discovery Opening Remarks James Mongan, MD President and CEO Partners HealthCare April 11, 2008.
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
Haematology Dr Victoria Hervey Chair Haematology NSSG North of England Cancer Network Annual Conference 20 September 2013.
100k Genomes Project Programme of Whole Genome Sequencing, part of UK Life Sciences Strategy Aim to sequence 100,000 genomes from patients with cancer.
Practice Based Commissioning. Who We Are Large PBC Consortium - 75 Practices, 351 GPs, 652,000 population Majority of Northamptonshire covered4 locality.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
1 Finding disease genes: A challenge for Medicine, Mathematics and Computer Science Andrew Collins, Professor of Genetic Epidemiology and Bioinformatics.
A comparison of somatic mutation callers in breast cancer samples and matched blood samples THOMAS BRETONNET BIOINFORMATICS AND COMPUTATIONAL BIOLOGY UNIT.
WiFi name: WifiLoveMCR Password: internet Join the conversation on Twitter using #DrivingChange
100,000 genomes project and haematological malignancy
Hereditary Cancer Predisposition: Updates in Genetic Testing
National Healthcare Science Week 2017
NISCHR Academic Health Science Collaboration Launch
Genomic Medicine Centre Overview
Overview: Designing better to give the best diabetes care
Web-based Tools for Integrative Analysis of Pancreatic Cancer Data
The 100,000 Genomes Project and the West of England Genomic Medicine Centre Brief update and overview provided by Catherine Carpenter-Clawson, Programme.
Results and Reporting:
Validation & Tumour Board – GM GMC Experience
100,000 Genomes Project & Mainstreaming Genomic Medicine
West of England Genomic Medicine Centre: Our Progress to Date
Pathway for patients with suspected Breast Cancer
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
The Genomics of Cancer and Molecular Testing:
Figure 1 The genomic nephrology workflow: genetic diagnosis and clinical application Figure 1 |The genomic nephrology workflow: genetic diagnosis and clinical.
Genomic Medicine Centre Overview
Introduction and Survey Results
Genomics Education Programme
Kirsty Russell Trainee Clinical Scientist (Bioinformatics – Genomics)
West of England Genomics Medicine Centre Overview
John Adler Chief Executive, Leicester’s Hospitals
Genomic Medicine Centre Overview
Genomics Tumour Advisory Board – our experience to date
Making MDTs better Steve Falk
100,000 Genomes Project & Mainstreaming Genomic Medicine
Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.
Anne Croudass, Cancer Research UK (United Kingdom)
High throughput genome study to identify predictors of aggressiveness in patients with sporadic desmoid tumor who undergo a wait and see approach Chiara.
100,000 Genomes Project & Mainstreaming Genomic Medicine
Mainstreaming Genomic Medicine post 100,000 Genomes Project
Research & scholarship
The Genetic Basis for Cancer Treatment Decisions
Cancer results pathway
IGV Demo and Data Management
100,000 Genomes Project & mainstreaming genomic medicine
Volume 155, Issue 6, Pages (December 2018)
GTAB/MTB working and terms of reference
PROSTATE CANCER CIRCULATING BIOMARKER CONSENSUS STATEMENT QUESTIONS
Multi-Disciplinary Team Meeting Reforms
Cancer WGS Analytical Pipeline Validation
Chris Wragg, Lead Cancer Scientist, SWGLH
100,000 Genomes Project & Mainstreaming Genomic Medicine
Genomic Medicine Centre Overview
Mary Alikian ICHT Cancer validation update
University of Edinburgh
100,000 Genomes Project & Mainstreaming Genomic Medicine
100,000 Genomes Project & Mainstreaming Genomic Medicine
100,000 Genomes Project & Mainstreaming Genomic Medicine
Pathway for patients with suspected Breast Cancer
Cancer Validation and Reporting Guidance Update 4th June 2016
Session 3: Coverage and Reimbursement for Genetic Testing
Cancer Nurse Coordinator Resource: MCH Perspective
NCRI and NHS England LWBC Event Somerset Cancer Register
Realistic Prescribing Pathways
Vylyny Chat, Robert Ferguson, Tomas Kirchhoff 
Presentation transcript:

Closing Cancer Cases Not Under Active Care Angela Douglas MBE Clinical Programme Director NW Coast Genomic Medicine Centre

Return of Results in Portal / Close Cases in Portal Not Validated Scientist/Clinician Identification of relevant genes/variants clinical trials Genomic MDT Group Validation Integrated report Tumour specific MDT Other diagnostic tests Clinical Discussion with patient about further treatment Relevant Results to patient Through follow up /when relapsed Results to clinician for review Decision about treatment Patient treatment

Presentation at MDT

Information for MDT Prepared by Scientist in collaboration with Clinician or Recruitment Nurse Patient: DOB: NHS No: Hospital No: Hospital Name: Consultant: Cancer Type: Subtype: Participant ID: Deceased: Patient is/ is not currently on an active pathway FF Not FFPE

List domain 1 somatic variants identified in report and highlight any relevant to patient List domain 2 somatic variants highlight any relevant to patient Highlight any pertinent structural variants of cancer genes Highlight any pertinent germline cancer susceptibility variants that were identified Number of somatic non-synonymous SNVs per megabase (coding region): x = ? =/ Not HIGH TMB

Mutation signature FF Not FFPE aetiology remains unknown likely due to tobacco mutagens ? deficient relevant signature

GTAB Decision outcome Following Discussion Outcomes from MDT: NO validation required at present patient has not reoccurred

Return of Results in Portal / Close Cases in Portal Not Validated Scientist/Clinician Identification of relevant genes/variants clinical trials Genomic MDT Group Validation Integrated report Tumour specific MDT Other diagnostic tests Clinical Discussion with patient about further treatment Relevant Results to patient Through follow up /when relapsed Results to clinician for review Decision about treatment Patient treatment